Is there a big difference between a biological agent and a targeted drug for psoriatic diseases?
Biologics were developed through modern biotechnology, and they had a clear targeting of the monoclone or antibody-fusion protein class of biomedicular drugs. Biologics approved for the treatment of psoriatic diseases in China mainly include tumor necrotic factor alpha (TN-alpha) inhibition agents (etanercepept, inflixed, and adamantine), IL- 23, IL - 12/23 inhibition agents (gustekinumab, ustekinumab), IL -17A inhibition agents (treasurekinumab, etc.), etc. From a cellular and molecular perspective, the overactive IL - 23/IL - 17 axis is the core pathological mechanism of plaque psoriatic plaque, and the IL - 17 family is the main effect factor in the pathogenic mechanism of psoriatic plaque and plays an important role in the development of the disease. In terms of small molecular targeted drugs, Apamilast was an oral, selective Phosphodiesterases 4 (PDE4) inhibition drug that regulated the network of pro-and anti-inflammatory mediator in cells. The two were different in terms of mechanism. Moreover, biologics were mainly large molecular drugs, while small molecular targeted drugs were different from biologics in terms of structure and mode of action, so the difference was large. Read more exciting novels for free
How long does the biological agent of pustular psoriatic take effect?
The effective time of biologics in the treatment of pustular psoriasisvaries from person to person. Generally speaking, biological agents for the treatment of psoriatic may be effective in 2 - 6 weeks, but if the condition is more serious or the patient's sensitivity to the drug is low, it may need to be extended to 3 months. However, there was currently no clear definition of the effective time of the biological agent for pustular psoriasis.The clinical application report showed that the biological agent may be effective for generalised pustular psoriasis.1 <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What is the difference between biological water purifying agent and water purifying agent?
Water purifying agent was a general term for a broad sense of the term. It was a drug that could react with other impurities in the water when put into the water. It mainly served the purpose of purifying water. It could be divided into two types: an organic flocculating agent (such as high-priced metal salt such as aluminum sulfuric acid, iron sulfuric acid, etc.) and an organic flocculating agent (such as polyacryl amine, polyacryl acid, etc.). It was commonly used in the sewage treatment industry such as metals, electricity, leather making, medicine, printing and dyeing, paper making, and chemical industry. Biological water purifying agent was a kind of agent that could improve the adaptability and decomposition ability of waste water by enhancing the activity of microorganisms in biochemical pool and increasing the population of microorganisms, thus improving the quality of water. There were mainly two kinds of agents: one was the agent that could improve the activity of microorganisms by combining various organic and mineral substances, and the other was the special purification of microorganisms (also known as biofulcating agent). The scope of application included the three-dimensional ecological environment in polluted rivers, lakes, ponds, drinking water sources and other water bodies. In addition to purifying the water, it could also suppress the growth of bacteria, remove water surface dirt, digest harmful components in the bottom mud, decompose the body of blue-green algae, and improve the quality of water. Therefore, the main difference between the two was in their composition, principle of action, and function. Water purifying agents remove impurities through chemical reactions, and most of their components are either organic or organic compounds. Biological water purifying agents mainly rely on the activity of microorganisms to purify water and have more diverse functions. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is it very troublesome to use biological agents for psoriatic patients?
It was not troublesome to get a biological agent for psoriatic patients. First, the doctor would assess the severity of the patient's psoriatic condition. The treatment plan and the use of biological agents could be determined based on the patient's body surface area (Body-surface Area), Skin Disease Area Severance Index (Pasi), Nail Damage Severance Index (NAPSI), and so on. Secondly, choose the appropriate biological agent. Currently, the commonly used biological agents were tumor factor alpha (TN)-alpha (TF-alpha), IL - 12/23, IL - 17, etc. Doctors would choose according to the patient's condition and treatment needs. After that, they would be treated with biological agents. The use of biological agents generally needed to be carried out under legal and regulated conditions in medical institutions. Finally, during the follow-up period after treatment, doctors needed to perform medical monitoring and drug safety monitoring on patients who were under biological agent treatment, adjust the treatment plan at any time, and monitor the patient's drug response and drug metabolism. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there a targeted drug for the spread of cervical cancer?
Yes. For example, anti-VegG drugs (such as bevacizhu), VegG is a pro-inflammatory factor that can promote the growth and spread of olive cancer cells, bevacizhu can block the binding of VegG to its receptor, and suppress the growth and migration of olive cancer cells;Parp inhibition drugs (such as olaparib) can prevent olive cancer cells from undergoing the correct DNA repair process, causing serious genetic mutations in cancer cells and death; ATR inhibition drugs (such as VE - 822). ATR is an important molecular response to DNA damage in cells. It will be activated after DNA double-strand breaks. VE - 822 can selectively inhibit ATR and promote the death of malignant tumor cells. Anti-HEL2 drugs (such as tocilbizumb). HEL2 is a targeted protein that is highly expressed in some patients with malignant tumors. Tocilbizumb can bind to HEL2 and suppress the growth and spread of malignant tumors. These targeted drugs could be combined with traditional surgery or chemotherapy to improve the treatment effect of the spread of the cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Brain tumor 2024 latest targeted drug
In 2024, there were some advancements in targeted drugs related to brain tumors: - Buritini: On April 23, 2024, it was approved in China for IDH mutant astrocytomas (World Health Organization grade 4) with the PTHRZ1-MET fusion gene or adult patients with glioblastomas with a low-grade medical history. This was the first fully approved small molecular targeted drug in the field of MET-targeted therapy for gliomas in China. In February 2021 and September 2022, the indications for lung cancer and gliomas were included as breakthrough treatments by the Center for Drug Evaluation (CDEs) of China's NMPA. The first indication was approved in November 2023 for the treatment of adult patients with locally advanced or metastasized non-small cell lung cancer (Lung cancer) with MET 14 mutation. - Servier's Voranigo (vorasidenib): approved by the US Food and Drug Administration on August 6, 2024, for the treatment of adult and child patients aged 12 years and older with grade 2 astrocytomas or oligodrenogliomas that are susceptible to IDH1 or IDH2 mutations. This is the first time that this type of grade 2 IDH-mutated brain cancer has been approved as a full-body therapy. Hurry up and click on the link below to return to the super classic "Lord of the Mysteries"!
Is the targeted drug for liver cancer metastasizing useful?
If liver cancer patients had metastasized, they could use targeted drugs, but they had to pay attention to their own condition. For patients with liver cancer lung metastasizing, they could take targeted drugs such as sorafenib, gefitini, or afatini. Sorafenib was more commonly used to treat untreatable or distant cancerous tumors. However, if there was severe liver function decline, large amounts of ascitic fluid, digestive tract bleeding, hepatic epilepsy, repeated infection, and other conditions, it was not suitable to use targeted drugs. At the same time, although targeted drugs had a certain effect on many liver cancer patients, some patients had no effect at all, and the cost was relatively high. Therefore, it was necessary to choose according to the individual's actual situation. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there a targeted drug for grade 3 brain stem gliomas?
The more commonly used gliomas targeted drugs were bevacizumi, anlotinib, imatini, gefitini, bevacizumi, and PD - 1. These drugs could be used for targeted therapy of gliomas, and may also be suitable for grade 3 brainstem gliomas. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there reimbursement for Changde lung cancer targeted drug?
Based on the information provided so far, it was impossible to determine whether Changde's targeted lung cancer drug was eligible for reimbursement. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there an imitation of the targeted drug for cervical cancer in India?
Yes, there was an Indian imitation version of the targeted drug. For example, there was an Indian version of Niraparini, but its price was difficult for ordinary family patients to afford. A box of Indian version of Niraparini cost about 20000 yuan. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there a targeted drug in the ribs of cardiac cancer metastasizing?
Cardia cancer with rib metastasizing was stage IV. For this case, Folfox protocol chemotherapy + anti-neoplastic drugs such as bevacizumi or cetuxed targeted therapy could be used. In addition, targeted drugs for the treatment of cardiac cancer also included erlotinib, gefitinib, nimotuzumab, pembrolizub, and so on. However, different targeted drugs had their own applications. For example, erlotinib was suitable for the treatment of patients with locally advanced, relapsed, or metastasized non-small cell lung cancer with mutations in the egF-receptor protein protein gene; Gefitini was used for the treatment of patients with locally advanced or metastasized non-small cell lung cancer who had failed at least one prior chemotherapy; Cetuxed was suitable for patients with wild-type RAS gene in the Coloreceptor Cancer; Nimotubiza is indicated for the auxiliary treatment of patients with stage III non-small cell lung cancer with positive expression of the Epidermal Growth factor receptor; pembrolizub is indicated for adult patients with positive expression of PD-L1 or anplastic large cell leukemia who have progressed during or after first-line systematic chemotherapy. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>